JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on March 26, 2009; DOI: 10.1124/jpet.108.150144


0022-3565/09/3293-1071-1083$20.00
JPET 329:1071-1083, 2009
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.108.150144v1
329/3/1071    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Zhu, J.
Right arrow Articles by Booze, R. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhu, J.
Right arrow Articles by Booze, R. M.

NEUROPHARMACOLOGY

HIV-1 Tat Protein-Induced Rapid and Reversible Decrease in [3H]Dopamine Uptake: Dissociation of [3H]Dopamine Uptake and [3H]2β-Carbomethoxy-3-β-(4-fluorophenyl)tropane (WIN 35,428) Binding in Rat Striatal Synaptosomes

Jun Zhu, Charles F. Mactutus, David R. Wallace, and Rosemarie M. Booze

Program in Behavioral Neuroscience, Department of Psychology, University of South Carolina, Columbia, South Carolina (J.Z., C.F.M., R.M.B.); and Department of Pharmacology and Physiology, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma (D.R.W.)

Human immunodeficiency virus (HIV)-1 Tat protein plays a key role in the pathogenesis of both HIV-1-associated cognitive-motor disorder and drug abuse. Dopamine (DA) transporter (DAT) function is strikingly altered in patients with HIV-1-associated dementia and a history of chronic drug abuse. This study is the first in vitro evaluation of potential mechanisms underlying the effects of Tat protein on DAT function. Rat striatal synaptosomes were incubated with recombinant Tat1–86 protein, and [3H]DA uptake and the binding of [3H]2β-carbomethoxy-3-β-(4-fluorophenyl)tropane (WIN 35,428) and [3H]1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)-piperazine (GBR 12935) were determined. Tat decreased [3H]DA uptake, [3H]WIN 35,428 binding, and [3H]GBR 12935 binding in a time-dependent manner. The potency of Tat for inhibiting [3H]DA uptake (Ki = 1.2 µM) was the same as that for inhibiting [3H]GBR 12935 binding but 3-fold less than that for inhibiting [3H]WIN 35,428 binding. Mutant Tat proteins did not alter [3H]DA uptake. Kinetic analysis of [3H]DA uptake revealed that Tat (1 or 10 µM) decreased the Vmax value and increased the Km value in a dose-dependent manner. The Vmax value, decreased by Tat (1 µM), returned to the control level after washout of Tat, indicating that the inhibitory effect of Tat on DA uptake was reversible. Saturation studies revealed that Tat decreased the Bmax value and increased the Kd value of [3H]WIN 35,428 binding, whereas Tat decreased the Bmax value of [3H]GBR 12935 binding, without a change in the Kd value. These findings provide new insight into understanding the pharmacological mechanisms of Tat-induced dysfunction of the DAT in the dopaminergic system in HIV-infected patients.


Received for publication December 20, 2008
Accepted March 25, 2009.

Address correspondence to: Dr. Jun Zhu, Program in Behavioral Neuroscience, Department of Psychology, University of South Carolina, 1512 Pendleton St., Columbia, SC 29208. E-mail: zhujun{at}mailbox.sc.edu







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2009 by the American Society for Pharmacology and Experimental Therapeutics.